What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

During the last several years, research has produced a significant amount of knowledge concerning the characteristics of human γδ T lymphocytes. Findings regarding the immune functions of these cells, particularly their natural killer cell-like lytic activity against tumor cells, have raised expecta...

Full description

Saved in:
Bibliographic Details
Published in:Cellular & molecular immunology 2013, Vol.10 (1), p.35-41
Main Authors: Fournié, Jean-Jacques, Sicard, Hélène, Poupot, Mary, Bezombes, Christine, Blanc, Amandine, Romagné, François, Ysebaert, Loic, Laurent, Guy
Format: Article
Language:English
Subjects:
Antibodies
Biomedical and Life Sciences
Biomedicine
Breast carcinoma
Cancer
Cancer immunotherapy
Chronic myeloid leukemia
Clinical trials
Clinical Trials as Topic
Hematology
Human health and pathology
Humans
Immunology
Immunotherapy
Immunotherapy - methods
Life Sciences
Lymphocytes T
Lymphoma
Malignancy
Medical Microbiology
Microbiology
Multiple myeloma
Myeloid leukemia
Natural killer cells
Neoplasms - immunology
Neoplasms - therapy
Prostate cancer
Prostate carcinoma
Receptors, Antigen, T-Cell, gamma-delta - immunology
Review
Solid tumors
T-Lymphocytes - immunology
Therapeutic applications
Tumor cells
Vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the last several years, research has produced a significant amount of knowledge concerning the characteristics of human γδ T lymphocytes. Findings regarding the immune functions of these cells, particularly their natural killer cell-like lytic activity against tumor cells, have raised expectations for the therapeutic applications of these cells for cancer. Pharmaceutical companies have produced selective agonists for these lymphocytes, and several teams have launched clinical trials of γδ T cell-based cancer therapies. The findings from these studies include hematological malignancies (follicular lymphoma, multiple myeloma, acute and chronic myeloid leukemia), as well as solid tumors (renal cell, breast and prostate carcinomas), consisting of samples from more than 250 patients from Europe, Japan and the United States. The results of these pioneering studies are now available, and this short review summarizes the lessons learned and the role of γδ T cell-based strategies in the current landscape of cancer immunotherapies.
ISSN:1672-7681
2042-0226
DOI:10.1038/cmi.2012.39